Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Open-label, Randomized Clinical Trial of Efficacy and Safety of the Thrombolysis With Recombinant Non-immunogenic Staphylokinase (Fortelyzin®) in Patients With ALI vs Surgery

NCT05372718 is registered in ClinicalTrials.gov with Supergene, LLC as lead sponsor.

NCT NCT05372718
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05372718 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Open-label, Randomized Clinical Trial of Efficacy and Safety of the Thrombolysis With Recombinant Non-immunogenic Staphylokinase (Fortelyzin®) in Patients With ALI vs Surgery
Lead sponsor
Supergene, LLC
Phase
Phase 3
Overall status
Completed
Start date
December 26, 2022
Completion date
September 30, 2026
Enrollment
170 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

acute limb ischemia